Evolus, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David Moatazedi
- Full Time Employees
- 350
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 520 Newport Center Drive Newport Beach CA United States of America 92660
- IPO Date
- Feb 8, 2018
- CIK
- 0001570562
- Website
- evolus.com
- Similar Companies
- Business
- Evolus, Inc. Evolus, Inc. (NASDAQ: EOLS), a performance beauty company, develops and commercializes aesthetic products in the cash-pay medical aesthetics market, including proprietary neurotoxin and dermal filler brands; its flagship Jeuveau (prabotulinumtoxinA-xvfs), a 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement of moderate to severe glabellar lines in adults, marketed as Nuceiva internationally; and Evolysse, a portfolio of injectable hyaluronic acid gels featuring Cold-X Technology for dynamic facial wrinkles such as nasolabial folds, with Estyme as the international counterpart. The company operates primarily in the United States, Canada, Europe including Great Britain, Germany and Austria, and Australia, targeting aesthetic practitioners such as dermatologists, plastic surgeons and medical spas, as well as cash-paying consumers, through a customer-centric model supported by digital platforms like the Evolus Practice App and Evolus Rewards loyalty program. Founded in 2012 and headquartered in Newport Beach, California, Evolus sources manufacturing from Daewoong Pharmaceutical Co., Ltd. in South Korea and focuses on commercialization rather than in-house production. In recent developments, Evolus launched Evolysse in the U.S. in 2025, achieving rapid sell-out of initial inventory and projecting it to contribute 10-12% of full-year revenue amid reaffirmed 2025 net revenue guidance of $295-$305 million; the company attained profitability in Q4 2024 and full-year 2024, ahead of schedule, driven by over 30% revenue growth for the fifth consecutive year. Evolus continues international Nuceiva expansion and advances its multi-product portfolio to capture share in the $7.4 billion global neurotoxin and filler market projected by 2028, with gross margins reaching approximately 68% through scale efficiencies.
Evolus to Report Second Quarter Financial Results on August 5, 2026
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
Evolus to Participate in The Jefferies Global Healthcare Conference
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
Evolus, Inc. (EOLS) Q1 2026 Earnings Call Transcript
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook
Evolus Targets Double-Digit Growth, Full-Year Profitability at Needham Healthcare Conference
Evolus to Report First Quarter Financial Results on May 4, 2026
JPMorgan Chase & Co. Decreases Stake in Evolus, Inc. $EOLS
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Evolus (NASDAQ:EOLS) Insider Sells $14,815.25 in Stock
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference
Evolus, Inc. (NASDAQ:EOLS) Receives $17.50 Average Target Price from Analysts
Why Evolus Stock Soared Today
Evolus, Inc. (EOLS) Q4 2025 Earnings Call Transcript
Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates
Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026